Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acorda Therapeutics, Inc.
Acorda Therapeutics To Present Phase 3 Fampridine-SR Data at World Congress on Treatment and Research in Multiple Sclerosis Meeting
October 3rd, 2008
Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that data from its recently-completed Fampridine-SR Phase 3 trial (MS-F204) will be presented during a poster session at the World Congress in Treatment and Research in MS Meeting (ACTRIMS, ECTRIMS and LACTRIMS) on Saturday, September 20, 2008 in Montreal, Canada. The Company previously announced top-line data from MS-F204 on June 2, 2008, and the poster will provide additional data from that clinical trial. The poster, "Sustained-Release Fampridine Consistently Improves Walking Speed And Leg Strength In Multiple Sclerosis: A Phase 3 Trial," will be presented by Andrew Goodman, M.D., Director of the Multiple Sclerosis...
Source: Health Business Week (2008-10-03)
|
